A targeted GLP-1-GIP-lanifibranol complex conferred broad metabolic benefits in obese mice, suggesting the potential of a new generation of multipathway therapies against obesity and type 2 diabetes.
Study: GLP-1R-GIPR-PPARα/γ/δ 5 heavy agonism improves obesity and diabetes in mice. Image credit: zimmytws / Shutterstock
Recent research published in journals nature We describe the creation of a novel single-molecule penta-agonist designed to integrate ranifibranol’s anti-inflammatory effects and insulin-sensitivity properties with incretin-mediated metabolic regulation.
In preclinical models, this compound showed superior efficacy to semaglutide and glucagon-like peptide-1 receptor (GLP-1R)-glucose-dependent insulinotropic polypeptide receptor (GIPR) combination therapy, significantly reducing body weight, food intake, and blood glucose levels in obese mice while delivering the drug at targeted low doses.
This finding supports targeted multipathway pharmacological strategies for common cardiometabolic diseases such as diabetes and obesity, but remains limited to preclinical evidence.
Background to incretin and PPAR agonist therapy
The therapeutic landscape of obesity and its metabolic complications has rapidly advanced with incretin-based therapies and nuclear receptor modulators. GLP-1R-GIPR coagonists, such as tirzepatide, have shown potent effects in reducing body weight, improving glycemic control, and even benefiting hepatic outcomes in metabolic dysfunction-associated steatohepatitis (MASH).
In parallel, peroxisome proliferator-activated receptor (PPAR) agonists, including the triple PPARα/γ/δ compound ranifibranol, currently in late-stage clinical development, have attracted attention for their metabolic and anti-inflammatory effects. However, incretin therapy may not completely resolve insulin resistance and inflammation, while PPAR agonists may have variable safety profiles, including weight changes and fluid imbalances, highlighting the need for new treatment strategies.
Pentavalent agonist research design and methods
To improve metabolic efficiency, in this study we developed and evaluated a single molecule penta-agonist that couples incretin-based signaling with peroxisome proliferator-activated receptor (PPAR) activity. Ranifibranol, a triple PPAR agonist targeting α, γ, and δ subtypes, was chemically conjugated to a dipeptidyl peptidase 4 (DPP4)-protected incretin coagonist backbone (MAR709). This design allowed selective uptake into cells expressing GLP-1 and GIP receptors.
The researchers randomly assigned the mice to treatment groups to ensure they were matched in genotype, age, weight, and overall body composition. Animals were injected subcutaneously (5.0 μL/g) with vehicle, semaglutide, and GLP-1 in combination with ranifibranol, GIP, or both at defined molar doses. In the primary efficacy experiment, the researchers treated mice with diet-induced obesity (DIO) for up to 12 days, including a regimen administering GLP-1-GIP-ranifibranol at doses of 5 to 50 nmol/kg.
The researchers evaluated metabolic outcomes using a battery of tolerance tests, including indirect calorimetry, body composition analysis, and glucose, insulin, and pyruvate tolerance tests in fasted mice. They also performed hyperinsulinemic-euglycemic clamp studies and tissue-specific glucose uptake assays to quantify insulin sensitivity and glucose disposal. They measured serum metabolites and hormones using enzyme-linked immunosorbent assay (ELISA).
At the molecular level, the team performed bulk ribonucleic acid sequencing (bulk RNA-seq) to analyze differential gene expression. They complemented these studies with in vitro experiments in human embryonic kidney 293T (HEK293T) cells, including bioluminescence resonance energy transfer (BRET) assays and quantification of PPAR-responsive gene activity. Proteomics, immunofluorescence, and conditioned taste avoidance testing further characterized the systemic and cellular effects of the drug. All in vivo metabolic evaluations were performed by blinded investigators.
Metabolic effects of GLP-1-GIP-ranifibranol
In vitro, the GLP-1–GIP–ranifibranol complex showed comparable incretin receptor activity and glucose-induced insulin secretion comparable to the GLP-1R–GIPR dual receptor scaffold. It also induced the expression of PPAR-related target genes to the same extent as ranifibranol, but only in cells expressing incretin receptors, confirming receptor-dependent activity. This targeted delivery strategy enabled pharmacological activity at ranifibranol exposures that were approximately 6,900 times lower than the dose of 30 mg/kg previously required to enhance hepatic metabolism in a preclinical setting.
In vivo, this single molecule conjugate showed superior efficacy compared to the combination of GLP-1R and GIPR activation, semaglutide, and a comparator regimen in both diet-induced and genetic obesity models, suggesting enhanced metabolic control. GLP-1-GIP-ranifibranor at 50 nmol/kg daily produced 2.63 times greater placebo-adjusted weight loss than GLP-1-ranifibranol after 14 days. Subsequent experiments identified a lead dose of 10 nmol/kg for further testing. These effects were accompanied by marked reductions in fat mass, dietary intake, and blood glucose levels, as well as improved oral glucose tolerance, enhanced insulin sensitivity, and strong suppression of endogenous glucose production, likely caused by reduced hepatic gluconeogenesis and systemic inflammatory activity.
Mechanistically, this treatment improved insulin sensitivity and glucose uptake, particularly in brown adipose tissue, and GLP-1-GIP-like glucose uptake in several other metabolic tissues, without increasing energy expenditure or promoting adipocyte differentiation. Transcriptome profiling identified over 5,400 differentially expressed genes in liver and over 8,000 in adipose tissue, indicating extensive remodeling of inflammatory and metabolic pathways.
Genetically or pharmacologically blocking GIP, GLP-1, or PPARδ signaling significantly reduces metabolic effects, supporting a combined incretin and PPAR mechanism of action. Consistently, mice lacking both incretin receptors showed a complete loss of activity, confirming that dual receptor engagement is required.
Preclinical impact on obesity and diabetes
This study highlights the possibility of combining incretin biology and nuclear receptor signaling for more comprehensive metabolic control. In preclinical models, the GLP-1-GIP-ranifibranol complex improved markers of body weight, blood sugar, glucose, liver, and cardiovascular function in mice, suggesting improved dosing efficiency and promoting preclinical safety signals, while using ranifibranol equivalent doses approximately 6,900-fold lower than the preclinical dose of 30 mg/kg previously required to improve liver metabolism. Translation of such multitarget strategies in humans could better address the growing global burden of obesity and type 2 diabetes, but clinical validation, human safety testing, and mechanistic clarification remain critical.
new @nature
Five-fold (GLP-1 + 4 other) receptor agonists exceed the effects of dual receptors (GLP-1 and GIP, tirzepatide) in experimental models versus diabetes and obesity
(If you think dual receptors are the biggest effect, triple receptors, as also seen with letaltortide… pic.twitter.com/bvjCbj5Y6P
– Eric Topol (@EricTopol) April 29, 2026
